Abstract | BACKGROUND AND OBJECTIVE: PATIENTS AND METHODS: Observational study that includes 21 haemolytic episodes occurred in 17 patients (9 males and 12 females), with a median age of 59 years (26-82). In group A, 8 episodes received IGIV + corticosteroids and in group B, 12 episodes received only corticosteroids and one rituximab. RESULTS:
Hemoglobin (Hb) value at diagnosis was 1.8 g/dl lower (95% confidence interval: 0.6 to 3.1; P = .007) in group A, with a median Hb of 6.3g/dl in this group vs 7.9 g/dl in group B. There were non-significant differences in red blood cells transfusion (50 vs 23%; P > .20) and global increase of Hb values (7.3 vs 5.6; P > .20). Overall hematological responses were similar: 88 vs 92% (P > .20). CONCLUSIONS: Hematological response achieved in more severe episodes with the use of IVIG was similar to non-severe episodes treated without IVIG.
|
Authors | Juan José Gil-Fernández, Elena Flores Ballester, María González Martínez, Juan Arévalo-Serrano, Ana Teresa Tamayo Martín, Carmen Burgaleta Alonso de Ozalla |
Journal | Medicina clinica
(Med Clin (Barc))
Vol. 141
Issue 5
Pg. 201-4
(Sep 07 2013)
ISSN: 1578-8989 [Electronic] Spain |
Vernacular Title | Inmunoglobulinas intravenosas en los episodios graves de anemia hemolítica autoinmune: resultados comparativos en 21 episodios de un único centro. |
PMID | 22857805
(Publication Type: Comparative Study, English Abstract, Journal Article, Observational Study)
|
Copyright | Copyright © 2012 Elsevier España, S.L. All rights reserved. |
Chemical References |
- Adrenal Cortex Hormones
- Antibodies, Monoclonal, Murine-Derived
- Hemoglobins
- Immunoglobulins, Intravenous
- Rituximab
|
Topics |
- Adrenal Cortex Hormones
(administration & dosage, therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Anemia, Hemolytic, Autoimmune
(blood, drug therapy, therapy)
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage, therapeutic use)
- Blood Cell Count
- Blood Transfusion
- Combined Modality Therapy
- Female
- Hemoglobins
(analysis)
- Hemolysis
- Humans
- Immunoglobulins, Intravenous
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Rituximab
- Treatment Outcome
|